Kangfang Biopharma’s new dual-antibody drug Ivoside is planned to be included in the breakthrough therapy designation for the treatment of triple-negative breast cancer
October 29, 2025
Source: drugdu
85
Shanghai Securities News China SecuritiesNet News (Reporter Zhang Xue) On October 24, Kangfang Bio 's Class 1 new drug PD-1/VEGF dual antibody Ivoside (AK112) injection was planned to be included in the breakthrough therapy variety. The indication is Ivosidemab combined with chemotherapy as the first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer.
Ivoside is a new dual-antibody drug with a synergistic anti-tumor mechanism of "tumor immunity + anti-angiogenesis." It simultaneously targets two important targets, PD-1 and VEGF, and synergistically exerts both tumor immunity and tumor anti-angiogenesis mechanisms, potentially providing a more effective treatment option for these patients.
In February 2025, Kangfang Bio announced that the first patient had been enrolled in the multicenter, randomized, double-blind Phase 3 clinical study (HARMONi-BC1/AK112-308) of Ivoside combination therapy as the first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Source：https://finance.eastmoney.com/a/202510243543410637.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
